Clinical Trial Update: Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ixazomib with dexamethasone and rituximab in untreated Waldenström's macroglobulinemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)
• ixazomib (ixazomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2020-09-02